Search PubMed⌕ Search

Biomedical subjects

R Valsecchi

Publications and source records attributed to R Valsecchi.

At least 55 records · Page 3Linked to original sources
PubMed1989

[Allergic contact dermatitis and oculorhinitis due to tulips].

A case of occupational allergic contact dermatitis with conjunctivitis and rhinitis due to tulips bulbs is described. The patient, aged 23, was employed in a florist storehouse. The dermatitis, affecting his hands, face, armpits, knees, elbows and ears, was accompanied by a rhinoconjunctivitis. Patch tests made with a tulip thin slice outcome positive results. The appearance, the way of arising and the results of the patch tests suggest the existence of an immediate type immunologic reaction (type I or IgE-dependent hypersensibility).

Adult↗
PubMed1989

[Von Willebrand factor multimers in systemic scleroderma].

In scleroderma endothelial cell damage plays an early and pivotal role in the pathogenesis of sclerotic lesions. In our study we determined whether or not plasma from 11 consecutive patients with scleroderma contained a subset of larger than normal (supranormal) multimers of von Willebrand factor which are potent inducers of platelet aggregation and adhesion. Supranormal multimers were found in all patients, but in none of the normal controls. Supranormal multimers may contribute to the pathogenesis of systemic sclerosis by inducing platelet aggregation and enhancing adhesion to subendothelium.

Adult↗
PubMed1988

HLA-DR and DQ antigens in lichen planus.

A study on HLA-DR and DQ typing in 40 patients with lichen planus (26 males and 14 females) and in 92 normal blood donors of both sexes was performed. Twenty-seven patients had cutaneous lesions, 11 cutaneous and mucosal involvement and 2 patients had oral erosive lesions. Serological typing revealed a highly significant increase of HLA-DR 1 antigen in the patient group. No difference has been observed on the prevalence of DR1 antigen among the different clinical status of the disease.

Adult↗
PubMed1986

Topical immunotherapy of alopecia areata. A follow-up study.

Ninety-six patients suffering from alopecia areata have been treated with topical immunotherapy. Fifty-one have been treated with dinitrochlorobenzene and 45 with squaric acid dibutylester. Analysis of our group showed that 55 patients out of those 96, who entered the study, experienced hair regrowth during a period of 6-17 weeks of treatment. Of these 55 patients, 25 (45.4%) had a recurrence of AA and 30 (53.6%) had a persistent regrowth during a follow-up of 16 months-6 years. The severity and early development of flare-up and induced allergic contact dermatitis have been the principal factors that have influenced the clinical results.

Administration, Topical↗
PubMed1986

Double-blind comparison of astemizole and terfenadine in the treatment of chronic urticaria.

Two new non-sedating antihistamines, astemizole (10 mg per day) and terfenadine (120 mg per day), were compared in a double-blind randomized study in 42 adult patients suffering from chronic urticaria. The trial lasted 4 weeks. Patients were evaluated at 2 and 4 weeks and kept a daily diary of their symptoms. There was a statistically significant decrease in pruritus, erythema and urticaria papules in both groups throughout the study. Changes in papule size, number and frequency were greater in the astemizole group though not significantly different to the terfenadine group. The effect of astemizole increased with time whereas that of terfenadine decreased after about 3 weeks of treatment. Astemizole was globally considered to be the most effective drug by both investigator and patients, with excellent/good results in 77% of the patients compared with 55% to 60% in the terfenadine group. Both drugs were reported to be more effective and faster acting than other antihistamines taken previously. Side-effects were infrequent and minor in both groups.

Adolescent↗